Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model
Markus Scholz1, Manuela Ackermann2, Frank Emmrich2, Markus Loeffler1, Manja Kamprad21Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Haertelstrasse 16–18, 04107 Leipzig, Germany; 2Institute for Clinical Immunology and Transfusion Medicine, Univers...
Guardado en:
Autores principales: | Markus Scholz, Manuela Ackermann, Frank Emmrich, Markus Loeffler, Manja Kamprad |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1facb487237a4d2da691d8d1eaeea656 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant.
por: Simone Cesaro, et al.
Publicado: (2013) -
Biosimilars in the management of neutropenia: focus on filgrastim
por: Caselli D, et al.
Publicado: (2016) -
Peripheral Blood Cytopenia and Risk of Cardiovascular Disease and Mortality
por: Radhika Gangaraju, et al.
Publicado: (2021) -
Characterization and comparability of biosimilars: A filgrastim case of study and regulatory perspectives for Latin America
por: Mendoza-Macedo,Karina, et al.
Publicado: (2016) -
The genetic analysis of Chinese patients with clonal cytopenias using targeted next-generation sequencing
por: Lijuan Zhang, et al.
Publicado: (2021)